Several other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Collegium Pharmaceutical from a hold rating to a sell rating in a report on Tuesday, January 7th. ValuEngine cut shares of Collegium Pharmaceutical from a buy rating to a hold rating in a report on Tuesday, January 7th. Needham & Company LLC reissued a buy rating and set a $28.00 target price on shares of Collegium Pharmaceutical in a report on Monday, January 6th. William Blair reissued a buy rating on shares of Collegium Pharmaceutical in a report on Tuesday, September 17th. Finally, SunTrust Banks raised their target price on shares of Collegium Pharmaceutical to $22.00 and gave the stock a buy rating in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Collegium Pharmaceutical presently has an average rating of Buy and a consensus target price of $28.71.
NASDAQ COLL opened at $20.95 on Wednesday. The company has a fifty day simple moving average of $21.35 and a two-hundred day simple moving average of $15.14. The stock has a market cap of $702.45 million, a P/E ratio of -61.62, a P/E/G ratio of 3.07 and a beta of 0.80. Collegium Pharmaceutical has a 12-month low of $10.01 and a 12-month high of $24.72. The company has a current ratio of 1.24, a quick ratio of 1.20 and a debt-to-equity ratio of 0.22.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.03). The company had revenue of $72.94 million during the quarter, compared to analysts’ expectations of $74.32 million. Collegium Pharmaceutical had a negative return on equity of 13.14% and a negative net margin of 3.86%. The company’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.50) EPS. As a group, sell-side analysts forecast that Collegium Pharmaceutical will post -0.64 earnings per share for the current year.
In other news, CEO Joseph Ciaffoni sold 64,821 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $18.77, for a total value of $1,216,690.17. Following the sale, the chief executive officer now owns 242,276 shares in the company, valued at $4,547,520.52. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 1,321 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $23.87, for a total transaction of $31,532.27. Following the completion of the sale, the executive vice president now owns 35,716 shares in the company, valued at approximately $852,540.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 386,429 shares of company stock worth $8,207,116. 8.08% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in COLL. Renaissance Technologies LLC acquired a new stake in shares of Collegium Pharmaceutical in the second quarter valued at about $3,210,000. Nuveen Asset Management LLC acquired a new position in Collegium Pharmaceutical during the second quarter worth about $2,622,000. BlackRock Inc. boosted its position in Collegium Pharmaceutical by 7.1% during the second quarter. BlackRock Inc. now owns 2,488,479 shares of the specialty pharmaceutical company’s stock worth $32,724,000 after acquiring an additional 165,018 shares during the last quarter. Eversept Partners LP acquired a new position in Collegium Pharmaceutical during the second quarter worth about $1,854,000. Finally, Bank of Montreal Can acquired a new position in Collegium Pharmaceutical during the second quarter worth about $1,573,000. Institutional investors and hedge funds own 89.58% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Recommended Story: Sell-Side Analysts
Receive News & Ratings for Collegium Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Collegium Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.